Shanghai Medicilon Inc. (SHA:688202)
28.31
-0.32 (-1.12%)
Last updated: Apr 28, 2025
Shanghai Medicilon Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 1,038 | 1,366 | 1,659 | 1,167 | 665.62 | Upgrade
|
Other Revenue | - | 0.03 | 0.06 | 0.76 | 0.34 | Upgrade
|
Revenue | 1,038 | 1,366 | 1,659 | 1,167 | 665.96 | Upgrade
|
Revenue Growth (YoY) | -24.01% | -17.68% | 42.12% | 75.28% | 48.19% | Upgrade
|
Cost of Revenue | 972.27 | 1,060 | 983.57 | 639.5 | 393.15 | Upgrade
|
Gross Profit | 65.47 | 305.74 | 675.36 | 527.76 | 272.8 | Upgrade
|
Selling, General & Admin | 195.03 | 220.18 | 204.09 | 132.28 | 87.39 | Upgrade
|
Research & Development | 96.73 | 122.39 | 122.88 | 77.76 | 44.9 | Upgrade
|
Other Operating Expenses | -9.86 | 3.28 | 2.28 | 0.73 | 0.43 | Upgrade
|
Operating Expenses | 281.9 | 389.92 | 352.76 | 219.29 | 137.82 | Upgrade
|
Operating Income | -216.43 | -84.17 | 322.6 | 308.47 | 134.98 | Upgrade
|
Interest Expense | - | -9.66 | -4.88 | -2.01 | - | Upgrade
|
Interest & Investment Income | 12.15 | 8.86 | 4.6 | 7.41 | 16.21 | Upgrade
|
Currency Exchange Gain (Loss) | - | -0.32 | 12.39 | -3.57 | -7.36 | Upgrade
|
Other Non Operating Income (Expenses) | -119.73 | -0.4 | 0.04 | -0.79 | -0.16 | Upgrade
|
EBT Excluding Unusual Items | -324.01 | -85.69 | 334.74 | 309.51 | 143.68 | Upgrade
|
Gain (Loss) on Sale of Investments | 0.56 | 3.23 | - | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | -0.01 | -0.34 | -0.87 | -1.04 | -1.38 | Upgrade
|
Asset Writedown | -57.61 | - | - | - | - | Upgrade
|
Other Unusual Items | - | 23.69 | 34.25 | 14.44 | 7.78 | Upgrade
|
Pretax Income | -381.08 | -59.1 | 368.11 | 322.91 | 150.08 | Upgrade
|
Income Tax Expense | -50.23 | -25.89 | 29.87 | 38.26 | 15.89 | Upgrade
|
Earnings From Continuing Operations | -330.85 | -33.21 | 338.24 | 284.65 | 134.19 | Upgrade
|
Minority Interest in Earnings | - | - | - | -2.42 | -4.8 | Upgrade
|
Net Income | -330.85 | -33.21 | 338.24 | 282.22 | 129.39 | Upgrade
|
Net Income to Common | -330.85 | -33.21 | 338.24 | 282.22 | 129.39 | Upgrade
|
Net Income Growth | - | - | 19.85% | 118.12% | 94.35% | Upgrade
|
Shares Outstanding (Basic) | 134 | 128 | 122 | 122 | 121 | Upgrade
|
Shares Outstanding (Diluted) | 134 | 128 | 122 | 122 | 121 | Upgrade
|
Shares Change (YoY) | 4.86% | 4.98% | 0.08% | 0.19% | 26.48% | Upgrade
|
EPS (Basic) | -2.47 | -0.26 | 2.78 | 2.32 | 1.07 | Upgrade
|
EPS (Diluted) | -2.47 | -0.26 | 2.78 | 2.32 | 1.07 | Upgrade
|
EPS Growth | - | - | 19.75% | 117.71% | 53.67% | Upgrade
|
Free Cash Flow | -133.14 | -152.36 | -425.39 | 160.22 | 89.05 | Upgrade
|
Free Cash Flow Per Share | -0.99 | -1.19 | -3.50 | 1.32 | 0.73 | Upgrade
|
Dividend Per Share | - | - | 0.279 | 0.699 | 0.321 | Upgrade
|
Dividend Growth | - | - | -60.14% | 117.49% | - | Upgrade
|
Gross Margin | 6.31% | 22.39% | 40.71% | 45.21% | 40.96% | Upgrade
|
Operating Margin | -20.86% | -6.16% | 19.45% | 26.43% | 20.27% | Upgrade
|
Profit Margin | -31.88% | -2.43% | 20.39% | 24.18% | 19.43% | Upgrade
|
Free Cash Flow Margin | -12.83% | -11.16% | -25.64% | 13.73% | 13.37% | Upgrade
|
EBITDA | -124.15 | -0.77 | 384.14 | 354.49 | 163.58 | Upgrade
|
EBITDA Margin | -11.96% | -0.06% | 23.16% | 30.37% | 24.56% | Upgrade
|
D&A For EBITDA | 92.28 | 83.41 | 61.54 | 46.01 | 28.6 | Upgrade
|
EBIT | -216.43 | -84.17 | 322.6 | 308.47 | 134.98 | Upgrade
|
EBIT Margin | -20.86% | -6.16% | 19.45% | 26.43% | 20.27% | Upgrade
|
Effective Tax Rate | - | - | 8.11% | 11.85% | 10.59% | Upgrade
|
Revenue as Reported | - | 1,366 | 1,659 | 1,167 | 665.96 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.